Do you want to read an article? Please log in or register.
Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: an ancillary study from the BLOCAGE trial
Lymphoma
Indications
Related content
Lymphoma
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies
Eur J Cancer
de Groot FA, Dekker TJA, Doorduijn JK, Böhringer S, Brink M, de Groen RAL, de Haan LM, Woei-A-Jin FJSH, Noordenbos T, Sijs-Szabo A, Oudshoorn MA, Lam KH, Diepstra A, Te Boome LCJ, Terpstra V, Bohmer LH, Nicolae A, Posthuma EFM, Koens L, Durian MF, Stavast J, van der Poel MWM, Hamid MA, Stevens WBC, van Rooij SLM, Oostvogels RS, Mühlebner A, Neelis KJ, van den Brand M, Tousseyn T, Dierickx D, de Weerdt O, Beeker A, Jansen PM, Kersten MJ, Zijlstra JM, Chamuleau MED, Veelken H, Bromberg JCE, Nijland M, Vermaat JSP
doi: 10.1016/j.ejca.2024.115068
Lymphoma
Outcomes and Relapse Patterns in Primary Central Nervous System Lymphoma: Longitudinal Analysis of 559 Patients Diagnosed From 1983-2020
Neuro Oncol
Tringale KR, Scordo M, Yahalom J, White C, Zhang Z, Vachha B, Cederquist G, Schaff L, DeAngelis L, Grommes C, Imber BS
doi: 10.1093/neuonc/noae115
Multiple Myeloma (MM)
Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group
Am J Hematol
Katodritou E, Dalampira D, Delimpasi S, Ntanasis-Stathopoulos I, Karaolidou F, Gkioka AI, Labropoulou V, Spanoudakis E, Triantafyllou T, Kotsopoulou M, Michalis E, Vadikolia C, Papadopoulou T, Sevastoudi A, Michael M, Daiou A, Pentidou A, Kostopoulos I, Palaska V, Gavriatopoulou M, Kyrtsonis MC, Verrou E, Kastritis E, Dimopoulos MA, Terpos E
doi: 10.1002/ajh.27425
Lymphoma
Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma
Blood
Gupta M, Bradley J, Massaad E, Burns E, Georgantas NZ, Maron G, Batten J, Gallagher A, Thierauf J, Nayyar N, Gordon A, Jones S, Pisapia M, Sun Y, Jones PS, Barker FG 2nd, Curry W, Gupta R, Romero J, Wang N, Brastianos P, Martinez-Lage M, Tateishi K, Forst DA, Nahed BV, Batchelor TT, Ritterhouse LL, Iser F, Kessler T, Jordan JT, Dietrich J, Meyerson ML, Cahill DP, Lennerz JK, Carter B, Shankar GM
doi: 10.1182/blood.2024023832
Lung, Respiratory and Thoracic Cancer
Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15)
Lung Cancer
Lee K, Kim TH, Yong Lee S, Lee YG, Choi J, Choi JH, Yoon Choi J, Lim AR, Sun Kim J, Won Lee J, Ji Choi Y, Hyun Park J, Namgung Y, Kyung Ahn H, Joo Kang E
doi: 10.1016/j.lungcan.2025.108455
Central Nervous System Tumors
Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions
Clin Cancer Res
Lamoureux AA, Fisher MJ, Lemelle L, Pfaff E, Amir-Yazdani P, Kramm C, De Wilde B, Kazanowska B, Hutter C, Pfister SM, Sturm D, Jones DTW, Orbach D, Pierron G, Raskin S, Drilon A, Diamond EL, Harada G, Zapotocky M, Zamecnik J, Krskova L, Ellezam B, Weil AG, Venne D, Barritault M, Leblond P, Coltin H, Hammad R, Tabori U, Hawkins C, Hansford JR, Meyran D, Erker C, McFadden K, Sato M, Gottardo NG, Dholaria H, Nørøxe DS, Goto H, Ziegler DS, Lin FY, Parsons DW, Lindsay H, Wong TT, Liu YL, Wu KS, Franson AT, Hwang E, Aguilar-Bonilla A, Cheng S, Cacciotti C, Massimino M, Schiavello E, Wood P, Hoffman LM, Cappellano A, Lassaletta A, Van Damme A, Llort A, Gerber NU, Spalato Ceruso M, Bendel AE, Skrypek M, Hamideh D, Mushtaq N, Walter A, Jabado N, Alsahlawi A, Farmer JP, Coleman C, Mueller S, Mazewski C, Aguilera D, Robison NJ, O'Halloran K, Abbou S, Berlanga P, Geoerger B, Øra I, Moertel CL, Razis ED, Vernadou A, Ducray F, Bronnimann C, Seizeur R, Clarke M, Resnick AC, Alves M, Jones C, Doz F, Laetsch TW, Perreault S
doi: 10.1158/1078-0432.CCR-24-0581
Breast Cancer
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Lancet Oncol
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC, CAPItello-291 study group
doi: 10.1016/S1470-2045(24)00373-5
Lymphoma
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study
Blood
Malinverni C, Bernardelli A, Glimelius I, Mirandola M, Ekstrom Smedby KE, Tisi MC, Giné E, Lindblad AA, Marin-Niebla AM, Di Rocco A, Moita F, Sciarra R, Bašić-Kinda S, Hess GR, Ohler A, Eskelund CW, Re A, Ferrarini I, Kolstad A, Räty RK, Quaglia FM, Eyre TA, Scapinello G, Stefani PM, Morello L, Nassi L, Hohaus S, Ragaini S, Zilioli VR, Bruna R, Cocito F, Arcari A, Jerkeman M, Visco C
doi: 10.1182/blood.2023023525
Sarcoma
Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 Trial
J Clin Oncol
Bisogno G, Chisholm J, Hladun R, De Salvo GL, Guerin F, Casanova M, Mandeville H, Alaggio R, Coppadoro B, Orbach D, Ferrari A, van Rijn R, Defachelles AS, Ben-Arush M, Glosli H, Cesen M, Merks JHM, Minard-Colin V
doi: 10.1200/JCO-24-02850